{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:38:44Z","timestamp":1790959124889,"version":"4.1.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Tumor cells often cope with elevated levels of replication stress (RS) causing increased dependency on ATR-CHK1 signaling. We previously presented RRM2, the regulatory component of the ribonucleotide reductase (RNR) enzyme, as novel dependency in neuroblastoma (NB), in keeping with its role in RS resistance. We identified strong synergism for combined RRM2-CHK1 inhibition using the iron chelator triapine and prexasertib respectively. To obtain direct RNR targeting, we evaluated a novel inhibitor, TAS1553, specifically disrupting the RNR complex in this study. Treatment with TAS1553 impedes cell growth and induces enhanced RS, DNA damage and apoptosis. We demonstrated strong synergism between TAS1553 and the CHK1 inhibitors prexasertib and SRA737 in both NB cell lines and tumoroids as well as in sarcoma cell lines. We confirm drug synergism in vivo in a NB zebrafish xenograft model, further underscoring the broad clinical potential of combinatorial RRM2-CHK1 inhibition. Altogether, this study paves the way for further preclinical testing of second generation RRM2 and CHK1 inhibitors such as TAS1553 and SRA737 in neuroblastoma and sarcomas.<\/jats:p>","DOI":"10.1038\/s41419-026-08514-6","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T17:55:50Z","timestamp":1772042150000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Targeting replication stress in neuroblastoma by exploiting the synergistic potential of second generation RRM2 and CHK1 inhibitors"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3382-8395","authenticated-orcid":false,"given":"Iris H.","family":"Nelen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7568-4660","authenticated-orcid":false,"given":"Soetkin","family":"Leys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4769-3460","authenticated-orcid":false,"given":"Sarah-Lee","family":"Bekaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"De Vloed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fien","family":"Martens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Sanders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angeline","family":"Praveena Enton Raj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Jeschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0930-5172","authenticated-orcid":false,"given":"Shunya","family":"Ohmura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0920-7377","authenticated-orcid":false,"given":"Thomas G. P.","family":"Gr\u00fcnewald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5738-0639","authenticated-orcid":false,"given":"Liselot M.","family":"Mus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8733-4027","authenticated-orcid":false,"given":"Tim","family":"Lammens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0247-2223","authenticated-orcid":false,"given":"Nadine","family":"Van Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bram","family":"De Wilde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6628-8559","authenticated-orcid":false,"given":"Frank","family":"Speleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5071-9369","authenticated-orcid":false,"given":"Annelies","family":"Van Hemelryk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5690-3258","authenticated-orcid":false,"given":"Lisa","family":"Depestel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1762-5739","authenticated-orcid":false,"given":"Kaat","family":"Durinck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"key":"8514_CR1","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/ncb2897","volume":"16","author":"MK Zeman","year":"2014","unstructured":"Zeman MK, Cimprich KA. Causes and consequences of replication stress. Nat Cell Biol. 2014;16:2\u20139.","journal-title":"Nat Cell Biol"},{"key":"8514_CR2","doi-asserted-by":"publisher","first-page":"3336","DOI":"10.1073\/pnas.1012351108","volume":"108","author":"KA Cole","year":"2011","unstructured":"Cole KA, Huggins J, Laquaglia M, Hulderman CE, Russell MR, Bosse K, et al. RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma. Proc Natl Acad Sci USA. 2011;108:3336\u201341.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8514_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejcped.2024.100177","volume":"4","author":"K Durinck","year":"2024","unstructured":"Durinck K, Irwin MS. DNA repair and replicative stress addiction in neuroblastoma. EJC Paediatr Oncol. 2024;4:100177.","journal-title":"EJC Paediatr Oncol"},{"key":"8514_CR4","doi-asserted-by":"publisher","first-page":"216","DOI":"10.18632\/oncotarget.27400","volume":"11","author":"WD Blosser","year":"2020","unstructured":"Blosser WD, Dempsey JA, McNulty AM, Rao X, Ebert PJ, Lowery CD, et al. A pan-cancer transcriptome analysis identifies replication fork and innate immunity genes as modifiers of response to the CHK1 inhibitor prexasertib. Oncotarget. 2020;11:216\u201336.","journal-title":"Oncotarget"},{"key":"8514_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27057-2","volume":"12","author":"J Szydzik","year":"2021","unstructured":"Szydzik J, Lind DE, Arefin B, Kurhe Y, Umapathy G, Siaw JT, et al. ATR inhibition enables complete tumour regression in ALK-driven NB mouse models. Nat Commun. 2021;12:6813.","journal-title":"Nat Commun"},{"key":"8514_CR6","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2315242121","volume":"121","author":"M Boren\u00e4s","year":"2024","unstructured":"Boren\u00e4s M, Umapathy G, Lind DE, Lai WY, Guan J, Johansson J, et al. ALK signaling primes the DNA damage response sensitizing ALK-driven neuroblastoma to therapeutic ATR inhibition. Proc Natl Acad Sci USA. 2024;121:e2315242121.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8514_CR7","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abn1382","volume":"8","author":"C Nunes","year":"2022","unstructured":"Nunes C, Depestel L, Mus L, Keller KM, Delhaye L, Louwagie A, et al. RRM2 enhances MYCN-driven neuroblastoma formation and acts as a synergistic target with CHK1 inhibition. Sci Adv. 2022;8:eabn1382.","journal-title":"Sci Adv"},{"key":"8514_CR8","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1038\/onc.2014.155","volume":"34","author":"Y Aye","year":"2014","unstructured":"Aye Y, Li M, Long MJC, Weiss RS. Ribonucleotide reductase and cancer: biological mechanisms and targeted therapies. Oncogene. 2014;34:2011\u201321.","journal-title":"Oncogene"},{"key":"8514_CR9","doi-asserted-by":"publisher","first-page":"17747","DOI":"10.1074\/jbc.M000799200","volume":"275","author":"A Chabes","year":"2000","unstructured":"Chabes A, Thelander L. Controlled protein degradation regulates ribonucleotide reductase activity in proliferating mammalian cells during the normal cell cycle and in response to DNA damage and replication blocks. J Biol Chem. 2000;275:17747\u201353.","journal-title":"J Biol Chem"},{"key":"8514_CR10","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.cell.2012.03.043","volume":"149","author":"V D\u2019Angiolella","year":"2012","unstructured":"D\u2019Angiolella V, Donato V, Forrester FM, Jeong YT, Pellacani C, Kudo Y, et al. Cyclin F-mediated degradation of ribonucleotide reductase M2 controls genome integrity and DNA repair. Cell. 2012;149:1023\u201334.","journal-title":"Cell"},{"key":"8514_CR11","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.lungcan.2022.07.010","volume":"171","author":"AA Bokhari","year":"2022","unstructured":"Bokhari AA, Lai WY, Le AT, Gabre JL, Chuang TP, Fransson S, et al. Novel human-derived EML4-ALK fusion cell lines identify ribonucleotide reductase RRM2 as a target of activated ALK in NSCLC. Lung Cancer. 2022;171:103\u201314.","journal-title":"Lung Cancer"},{"key":"8514_CR12","doi-asserted-by":"publisher","first-page":"3518","DOI":"10.18632\/aging.202292","volume":"13","author":"CY Jin","year":"2020","unstructured":"Jin CY, Du L, Nuerlan AH, Wang XL, Yang YW, Guo R. High expression of RRM2 as an independent predictive factor of poor prognosis in patients with lung adenocarcinoma. Aging (Albany NY). 2020;13:3518\u201335.","journal-title":"Aging (Albany NY)"},{"key":"8514_CR13","doi-asserted-by":"publisher","first-page":"4480","DOI":"10.1158\/1078-0432.CCR-18-4046","volume":"25","author":"YZ Mazzu","year":"2019","unstructured":"Mazzu YZ, Armenia J, Chakraborty G, Yoshikawa Y, Coggins SA, Nandakumar S, et al. A novel mechanism driving poor-prognosis prostate cancer: Overexpression of the DNA repair gene, ribonucleotide reductase small subunit M2 (RRM2). Clin Cancer Res. 2019;25:4480\u201392.","journal-title":"Clin Cancer Res"},{"key":"8514_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111396","volume":"40","author":"L Granieri","year":"2022","unstructured":"Granieri L, Marocchi F, Melixetian M, Mohammadi N, Nicoli P, Cuomo A, et al. Targeting the USP7\/RRM2 axis drives senescence and sensitizes melanoma cells to HDAC\/LSD1 inhibitors. Cell Rep. 2022;40:111396.","journal-title":"Cell Rep"},{"key":"8514_CR15","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1158\/1541-7786.MCR-16-0099","volume":"14","author":"N Fatkhutdinov","year":"2016","unstructured":"Fatkhutdinov N, Sproesser K, Krepler C, Liu Q, Brafford PA, Herlyn M, et al. Targeting RRM2 and mutant BRAF is a novel combinatorial strategy for melanoma. Mol Cancer Res. 2016;14:767\u201375.","journal-title":"Mol Cancer Res"},{"key":"8514_CR16","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1158\/1541-7786.MCR-19-0585","volume":"18","author":"SL Koppenhafer","year":"2020","unstructured":"Koppenhafer SL, Goss KL, Terry WW, Gordon DJ. Inhibition of the ATR-CHK1 pathway in Ewing sarcoma cells causes DNA damage and apoptosis via the CDK2-mediated degradation of RRM2. Mol Cancer Res. 2020;18:91\u2013104.","journal-title":"Mol Cancer Res"},{"key":"8514_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01393-9","volume":"20","author":"S Ohmura","year":"2021","unstructured":"Ohmura S, Marchetto A, Orth MF, Li J, Jabar S, Ranft A, et al. Translational evidence for RRM2 as a prognostic biomarker and therapeutic target in Ewing sarcoma. Mol Cancer. 2021;20:97.","journal-title":"Mol Cancer"},{"key":"8514_CR18","doi-asserted-by":"publisher","first-page":"12800","DOI":"10.1080\/21655979.2021.2001241","volume":"12","author":"M Yang","year":"2021","unstructured":"Yang M, Yao P, Lang X, Li X, Zhang D. Ribonucleotide reductase subunit M2 promotes proliferation and epithelial\u2013mesenchymal transition via the JAK2\/STAT3 signaling pathway in retinoblastoma. Bioengineered. 2021;12:12800\u201311.","journal-title":"Bioengineered"},{"key":"8514_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2024.101075","volume":"58","author":"LH Giang","year":"2024","unstructured":"Giang LH, Wu KS, Lee WC, Chu SS, Do AD, Huang MH, et al. RRM2 inhibition alters cell cycle through ATM\/Rb\/E2F1 pathway in atypical teratoid rhabdoid tumor. Neoplasia. 2024;58:101075.","journal-title":"Neoplasia"},{"key":"8514_CR20","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1186\/s13046-023-02911-x","volume":"42","author":"LH Giang","year":"2023","unstructured":"Giang LH, Wu KS, Lee WC, Chu SS, Do AD, Changou CA, et al. Targeting of RRM2 suppresses DNA damage response and activates apoptosis in atypical teratoid rhabdoid tumor. J Exp Clin Cancer Res. 2023;42:346.","journal-title":"J Exp Clin Cancer Res"},{"key":"8514_CR21","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s42003-023-04630-7","volume":"6","author":"A Brown","year":"2023","unstructured":"Brown A, Pan Q, Fan L, Indersie E, Tian C, Timchenko N, et al. Ribonucleotide reductase subunit switching in hepatoblastoma drug response and relapse. Commun Biol. 2023;6:249.","journal-title":"Commun Biol"},{"key":"8514_CR22","doi-asserted-by":"publisher","first-page":"7464","DOI":"10.1016\/S0021-9258(19)43313-9","volume":"248","author":"CL Atkin","year":"1973","unstructured":"Atkin CL, Thelander L, Reichard P, Lang G. Iron and Free Radical in Ribonucleotide Reductase: EXCHANGE OF IRON AND M\u00d6SSBAUER SPECTROSCOPY OF THE PROTEIN B2 SUBUNIT OF THE ESCHERICHIA COLI ENZYME. J Biol Chem. 1973;248:7464\u201372.","journal-title":"J Biol Chem"},{"key":"8514_CR23","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/0006-291X(92)91138-G","volume":"188","author":"G Lassmann","year":"1992","unstructured":"Lassmann G, Thelander L, Gr\u00e4slund A. EPR stopped-flow studies of the reaction of the tyrosyl radical of protein r2 from ribonucleotide reductase with hydroxyurea. Biochem Biophys Res Commun. 1992;188:879\u201387.","journal-title":"Biochem Biophys Res Commun"},{"key":"8514_CR24","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1158\/1535-7163.MCT-05-0384","volume":"5","author":"J Shao","year":"2006","unstructured":"Shao J, Zhou B, Di Bilio AJ, Zhu L, Wang T, Qi C, et al. A Ferrous-triapine complex mediates formation of reactive oxygen species that inactivate human ribonucleotide reductase. Mol Cancer Ther. 2006;5:586\u201392.","journal-title":"Mol Cancer Ther"},{"key":"8514_CR25","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s10637-007-9044-9","volume":"25","author":"JJ Knox","year":"2007","unstructured":"Knox JJ, Hotte SJ, Kollmannsberger C, Winquist E, Fisher B, Eisenhauer EA. Phase II study of Triapine in patients with metastatic renal cell carcinoma: A trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC IND.161). Invest N Drugs. 2007;25:471\u20137.","journal-title":"Invest N Drugs"},{"key":"8514_CR26","doi-asserted-by":"publisher","first-page":"110996","DOI":"10.1016\/j.biopha.2020.110996","volume":"133","author":"Y Zhan","year":"2021","unstructured":"Zhan Y, Jiang L, Jin X, Ying S, Wu Z, Wang L, et al. Inhibiting RRM2 to enhance the anticancer activity of chemotherapy. Biomedicine Pharmacother. 2021;133:110996.","journal-title":"Biomedicine Pharmacother"},{"key":"8514_CR27","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.chembiol.2021.02.006","volume":"28","author":"DE Scott","year":"2021","unstructured":"Scott DE, Francis-Newton NJ, Marsh ME, Coyne AG, Fischer G, Moschetti T, et al. A small-molecule inhibitor of the BRCA2-RAD51 interaction modulates RAD51 assembly and potentiates DNA damage-induced cell death. Cell Chem Biol. 2021;28:835\u201347.","journal-title":"Cell Chem Biol"},{"key":"8514_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2023.117383","volume":"90","author":"X Zhang","year":"2023","unstructured":"Zhang X, Chen X, Lu L, Fang Q, Liu C, Lin Z. Identification of small-molecule inhibitors of human MUS81-EME1\/2 by FRET-based high-throughput screening. Bioorg Med Chem. 2023;90:117383.","journal-title":"Bioorg Med Chem"},{"key":"8514_CR29","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1038\/s42003-022-03516-4","volume":"5","author":"H Ueno","year":"2022","unstructured":"Ueno H, Hoshino T, Yano W, Tsukioka S, Suzuki T, Hara S, et al. TAS1553, a small molecule subunit interaction inhibitor of ribonucleotide reductase, exhibits antitumor activity by causing DNA replication stress. Commun Biol. 2022;5:571.","journal-title":"Commun Biol"},{"key":"8514_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216308","volume":"570","author":"S Corrales-Guerrero","year":"2023","unstructured":"Corrales-Guerrero S, Cui T, Castro-Aceituno V, Yang L, Nair S, Feng H, et al. Inhibition of RRM2 radiosensitizes glioblastoma and uncovers synthetic lethality in combination with targeting CHK1. Cancer Lett. 2023;570:216308.","journal-title":"Cancer Lett"},{"key":"8514_CR31","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/s41568-023-00557-7","volume":"23","author":"NJ Mullen","year":"2023","unstructured":"Mullen NJ, Singh PK. Nucleotide metabolism: a pan-cancer metabolic dependency. Nat Rev Cancer. 2023;23:275\u201394.","journal-title":"Nat Rev Cancer"},{"key":"8514_CR32","doi-asserted-by":"publisher","first-page":"e202301933","DOI":"10.26508\/lsa.202301933","volume":"6","author":"M Ozgencil","year":"2023","unstructured":"Ozgencil M, Dullovi A, Higos RCC, Ho\u0159ej\u0161\u00ed Z, Bellelli R. The linker histone H1\u2013BRCA1 axis is a crucial mediator of replication fork stability. Life Sci Alliance. 2023;6:e202301933.","journal-title":"Life Sci Alliance"},{"key":"8514_CR33","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.molcel.2016.03.013","volume":"62","author":"JL Tan","year":"2016","unstructured":"Tan JL, Fogley RD, Flynn RA, Ablain J, Yang S, Saint-Andr\u00e9 V, et al. Stress from nucleotide depletion activates the transcriptional regulator HEXIM1 to suppress melanoma. Mol Cell. 2016;62:34\u201346.","journal-title":"Mol Cell"},{"key":"8514_CR34","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adk8908","volume":"10","author":"J Ma","year":"2024","unstructured":"Ma J, Ren D, Wang Z, Li W, Li L, Liu T, et al. CK2-dependent degradation of CBX3 dictates replication fork stalling and PARP inhibitor sensitivity. Sci Adv. 2024;10:eadk8908.","journal-title":"Sci Adv"},{"key":"8514_CR35","doi-asserted-by":"publisher","first-page":"4783","DOI":"10.3390\/cancers13194783","volume":"13","author":"De Wyn","year":"2021","unstructured":"De Wyn, Zimmerman J, Weichert MW, leahey N, Nunes C, Cheung BB, et al. MEIS2 is an adrenergic core regulatory transcription factor involved in early initiation of TH-MYCN-driven neuroblastoma formation. Cancers (Basel). 2021;13:4783.","journal-title":"Cancers (Basel)"},{"key":"8514_CR36","first-page":"105","volume":"38","author":"PL Regan","year":"2011","unstructured":"Regan PL, Jacobs J, Wang G, Torres J, Edo R, Friedmann J, et al. Hsp90 inhibition increases p53 expression and destabilizes MYCN and MYC in neuroblastoma. Int J Oncol. 2011;38:105\u201312.","journal-title":"Int J Oncol"},{"key":"8514_CR37","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1530\/ERC-11-0207","volume":"18","author":"F Lamers","year":"2011","unstructured":"Lamers F, Van Der Ploeg I, Schild L, Ebus ME, Koster J, Hansen BR, et al. Knockdown of survivin (BIRC5) causes apoptosis in neuroblastoma via mitotic catastrophe. Endocr Relat Cancer. 2011;18:657\u201368.","journal-title":"Endocr Relat Cancer"},{"key":"8514_CR38","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/s41388-020-01552-0","volume":"40","author":"KL Goss","year":"2021","unstructured":"Goss KL, Koppenhafer SL, Waters T, Terry WW, Wen KK, Wu M, et al. The translational repressor 4E-BP1 regulates RRM2 levels and functions as a tumor suppressor in Ewing sarcoma tumors. Oncogene. 2021;40:564\u201377.","journal-title":"Oncogene"},{"key":"8514_CR39","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1089\/zeb.2024.0160","volume":"21","author":"JM Lawrence","year":"2024","unstructured":"Lawrence JM, Tan SH, Kim DC, Tan KE, Schroeder SE, Yeo KS, et al. Diverse engraftment capability of neuroblastoma cell lines in zebrafish larvae. Zebrafish. 2024;21:385\u201393.","journal-title":"Zebrafish"},{"key":"8514_CR40","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1158\/1535-7163.MCT-14-1037","volume":"14","author":"C King","year":"2015","unstructured":"King C, Diaz HB, McNeely S, Barnard D, Dempsey J, Blosser W, et al. LY2606368 causes replication catastrophe and antitumor effects through CHK1-dependent mechanisms. Mol Cancer Ther. 2015;14:2004\u201313.","journal-title":"Mol Cancer Ther"},{"key":"8514_CR41","doi-asserted-by":"publisher","first-page":"5221","DOI":"10.1021\/acs.jmedchem.5b01938","volume":"59","author":"JD Osborne","year":"2016","unstructured":"Osborne JD, Matthews TP, McHardy T, Proisy N, Cheung KMJ, Lainchbury M, et al. Multiparameter lead optimization to give an oral Checkpoint Kinase 1 (CHK1) inhibitor clinical candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737). J Med Chem. 2016;59:5221\u201337.","journal-title":"J Med Chem"},{"key":"8514_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-024-03356-8","volume":"24","author":"Y Yao","year":"2024","unstructured":"Yao Y, Zhang Q, Li Z, Zhang H. MDM2: current research status and prospects of tumor treatment. Cancer Cell Int. 2024;24:170.","journal-title":"Cancer Cell Int"},{"key":"8514_CR43","doi-asserted-by":"publisher","first-page":"19190","DOI":"10.1073\/pnas.1208215109","volume":"109","author":"LJ Valentijn","year":"2012","unstructured":"Valentijn LJ, Koster J, Haneveld F, Aissa RA, Van Sluis P, Broekmans MEC, et al. Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification. Proc Natl Acad Sci USA. 2012;109:19190\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8514_CR44","doi-asserted-by":"publisher","first-page":"3327","DOI":"10.1158\/1078-0432.CCR-14-2024","volume":"21","author":"I Lambertz","year":"2015","unstructured":"Lambertz I, Kumps C, Claeys S, Lindner S, Beckers A, Janssens E, et al. Upregulation of MAPK negative feedback regulators and RET in mutant ALK neuroblastoma: Implications for targeted treatment. Clin Cancer Res. 2015;21:3327\u201339.","journal-title":"Clin Cancer Res"},{"key":"8514_CR45","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1038\/ng.3899","volume":"49","author":"T Van Groningen","year":"2017","unstructured":"Van Groningen T, Koster J, Valentijn LJ, Zwijnenburg DA, Akogul N, Hasselt NE, et al. Neuroblastoma is composed of two super-enhancer-associated differentiation states. Nat Genet. 2017;49:1261\u20136.","journal-title":"Nat Genet"},{"key":"8514_CR46","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1146\/annurev-biochem-091719-064225","volume":"89","author":"ME Wilkinson","year":"2020","unstructured":"Wilkinson ME, Charenton C, Nagai K. RNA splicing by the spliceosome. Annu Rev Biochem. 2020;89:359\u201388.","journal-title":"Annu Rev Biochem"},{"key":"8514_CR47","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature14548","volume":"523","author":"THD Nguyen","year":"2015","unstructured":"Nguyen THD, Galej WP, Bai XC, Savva CG, Newman AJ, Scheres SHW, et al. The architecture of the spliceosomal U4\/U6.U5 tri-snRNP. Nature. 2015;523:47\u201352.","journal-title":"Nature"},{"key":"8514_CR48","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.3390\/biom5042935","volume":"5","author":"L Shkreta","year":"2015","unstructured":"Shkreta L, Chabot B. The RNA splicing response to DNA damage. Biomolecules. 2015;5:2935\u201377.","journal-title":"Biomolecules"},{"key":"8514_CR49","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.molcel.2009.06.021","volume":"35","author":"RD Paulsen","year":"2009","unstructured":"Paulsen RD, Soni DV, Wollman R, Hahn AT, Yee MC, Guan A, et al. A genome-wide siRNA screen reveals diverse cellular processes and pathways that mediate genome stability. Mol Cell. 2009;35:228\u201339.","journal-title":"Mol Cell"},{"key":"8514_CR50","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1002\/cpt196455574","volume":"5","author":"WN Fishbein","year":"1964","unstructured":"Fishbein WN, Carbone PP, Freireich EJ, Misra D, Frei E. Clinical trials of hydroxyurea in patients with cancer and leukemia. Clin Pharm Ther. 1964;5:574\u201380.","journal-title":"Clin Pharm Ther"},{"key":"8514_CR51","doi-asserted-by":"publisher","first-page":"e215","DOI":"10.1097\/MD.0000000000000215","volume":"93","author":"JS Hankins","year":"2014","unstructured":"Hankins JS, Aygun B, Nottage K, Thornburg C, Smeltzer MP, Ware RE, et al. From infancy to adolescence: Fifteen years of continuous treatment With hydroxyurea in sickle cell anemia. Med (Baltim). 2014;93:e215.","journal-title":"Med (Baltim)"},{"key":"8514_CR52","first-page":"3686","volume":"54","author":"Y Yen","year":"1994","unstructured":"Yen Y, Grill SP, Dutschman GE, Chang CN, Zhou BS, Cheng YC. Characterization of a hydroxyurea-resistant human KB cell line with supersensitivity to 6-thioguanine. Cancer Res. 1994;54:3686\u201391.","journal-title":"Cancer Res"},{"key":"8514_CR53","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1023\/A:1006559901771","volume":"16","author":"BSen Zhou","year":"1998","unstructured":"Zhou BSen, Tsai P, Ker R, Tsai J, Ho R, Yu J, et al. Overexpression of transfected human ribonucleotide reductase M2 subunit in human cancer cells enhances their invasive potential. Clin Exp Metastasis. 1998;16:43\u20139.","journal-title":"Clin Exp Metastasis"},{"key":"8514_CR54","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/S0006-2952(99)00419-0","volume":"59","author":"RA Finch","year":"2000","unstructured":"Finch RA, Liu MC, Grill SP, Rose WC, Loomis R, Vasquez KM, et al. Triapine (3-aminopyridine-2-carboxaldehyde- thiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity. Biochem Pharm. 2000;59:983\u201391.","journal-title":"Biochem Pharm"},{"key":"8514_CR55","first-page":"6110","volume":"51","author":"P Huang","year":"1991","unstructured":"Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W. Action of 2\u2019,2\u2019-difluorodeoxycytidine on DNA synthesis. Cancer Res. 1991;51:6110\u20137.","journal-title":"Cancer Res"},{"key":"8514_CR56","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/S0026-895X(25)09518-5","volume":"38","author":"V Heinemann","year":"1990","unstructured":"Heinemann V, Xu YZ, Chubb S, Sen A, Hertel LW, Grindey GB, et al. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2\u2019,2\u2019-difluorodeoxycytidine. Mol Pharm. 1990;38:567\u201372.","journal-title":"Mol Pharm"},{"key":"8514_CR57","doi-asserted-by":"publisher","first-page":"4028","DOI":"10.1073\/pnas.0600440103","volume":"103","author":"H Xu","year":"2006","unstructured":"Xu H, Faber C, Uchiki T, Racca J, Dealwis C. Structures of eukaryotic ribonucleotide reductase I define gemcitabine diphosphate binding and subunit assembly. Proc Natl Acad Sci USA. 2006;103:4028\u201333.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8514_CR58","doi-asserted-by":"publisher","first-page":"9114","DOI":"10.1016\/S0021-9258(17)39337-7","volume":"260","author":"Y Engstr\u00f6m","year":"1985","unstructured":"Engstr\u00f6m Y, Eriksson S, Jildevik I, Skog S, Thelander L, Tribukait B. Cell cycle-dependent expression of mammalian ribonucleotide reductase. Differential regulation of the two subunits. J Biol Chem. 1985;260:9114\u20136.","journal-title":"J Biol Chem"},{"key":"8514_CR59","doi-asserted-by":"publisher","first-page":"38022","DOI":"10.18632\/oncotarget.16723","volume":"8","author":"RB Mokhtari","year":"2017","unstructured":"Mokhtari RB, Homayouni TS, Baluch N, Morgatskaya E, Kumar S, Das B, et al. Combination therapy in combating cancer. Oncotarget. 2017;8:38022\u201343.","journal-title":"Oncotarget"},{"key":"8514_CR60","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1021\/acsptsci.0c00201","volume":"4","author":"JP Ditano","year":"2021","unstructured":"Ditano JP, Eastman A. Comparative activity and off-target effects in cells of the CHK1 inhibitors MK-8776, SRA737, and LY2606368. ACS Pharm Transl Sci. 2021;4:730\u201343.","journal-title":"ACS Pharm Transl Sci"},{"key":"8514_CR61","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1002\/1878-0261.12573","volume":"13","author":"PM Schoonen","year":"2019","unstructured":"Schoonen PM, Kok YP, Wierenga E, Bakker B, Foijer F, Spierings DCJ, et al. Premature mitotic entry induced by ATR inhibition potentiates olaparib inhibition-mediated genomic instability, inflammatory signaling, and cytotoxicity in BRCA2-deficient cancer cells. Mol Oncol. 2019;13:2422\u201340.","journal-title":"Mol Oncol"},{"key":"8514_CR62","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1172\/JCI123319","volume":"129","author":"RM Chabanon","year":"2019","unstructured":"Chabanon RM, Muirhead G, Krastev DB, Adam J, Morel D, Garrido M, et al. PARP inhibition enhances tumor cell\u2013intrinsic immunity in ERCC1-deficient non\u2013small cell lung cancer. J Clin Invest. 2019;129:1211\u201328.","journal-title":"J Clin Invest"},{"key":"8514_CR63","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.ado4618","volume":"10","author":"H Taniguchi","year":"2024","unstructured":"Taniguchi H, Chakraborty S, Takahashi N, Banerjee A, Caeser R, Zhan YA, et al. ATR inhibition activates cancer cell cGAS\/STING-interferon signaling and promotes antitumor immunity in small-cell lung cancer. Sci Adv. 2024;10:eado4618.","journal-title":"Sci Adv"},{"key":"8514_CR64","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.3390\/cancers12102912","volume":"12","author":"L Blavier","year":"2020","unstructured":"Blavier L, Yang RM, Declerck YA. The tumor microenvironment in neuroblastoma: New players, new mechanisms of interaction and new perspectives. Cancers (Basel). 2020;12:2912.","journal-title":"Cancers (Basel)"},{"key":"8514_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/oncsis.2016.70","volume":"5","author":"M Tanikawa","year":"2016","unstructured":"Tanikawa M, Sanjiv K, Helleday T, Herr P, Mortusewicz O. The spliceosome U2 snRNP factors promote genome stability through distinct mechanisms; transcription of repair factors and R-loop processing. Oncogenesis. 2016;5:e280.","journal-title":"Oncogenesis"},{"key":"8514_CR66","doi-asserted-by":"publisher","first-page":"5363","DOI":"10.1158\/0008-5472.CAN-17-3970","volume":"78","author":"HD Nguyen","year":"2018","unstructured":"Nguyen HD, Leong WY, Li W, Reddy PNG, Sullivan JD, Walter MJ, et al. Spliceosome mutations induce R loop-associated sensitivity to ATR inhibition in myelodysplastic syndrome. Cancer Res. 2018;78:5363\u201374.","journal-title":"Cancer Res"},{"key":"8514_CR67","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-020-00220-5","volume":"8","author":"Z Zhou","year":"2020","unstructured":"Zhou Z, Gong Q, Wang Y, Li M, Wang L, Ding H, et al. The biological function and clinical significance of SF3B1 mutations in cancer. Biomark Res. 2020;8:38.","journal-title":"Biomark Res"},{"key":"8514_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115275","volume":"218","author":"KPS Langenberg","year":"2025","unstructured":"Langenberg KPS, van Hooff SR, Koopmans B, Strijker JGM, Kholosy WM, Ober K, et al. Exploring high-throughput drug sensitivity testing in neuroblastoma cell lines and patient-derived tumor organoids in the era of precision medicine. Eur J Cancer. 2025;218:115275.","journal-title":"Eur J Cancer"},{"key":"8514_CR69","doi-asserted-by":"publisher","first-page":"e0296322","DOI":"10.1371\/journal.pone.0296322","volume":"19","author":"C Nunes","year":"2024","unstructured":"Nunes C, Anckaert J, De Vloed F, De Wyn J, Durinck K, Vandesompele J, et al. HTSplotter: An end-to-end data processing, analysis and visualisation tool for chemical and genetic in vitro perturbation screening. PLoS One. 2024;19:e0296322.","journal-title":"PLoS One"},{"key":"8514_CR70","doi-asserted-by":"publisher","first-page":"W739","DOI":"10.1093\/nar\/gkac382","volume":"50","author":"A Ianevski","year":"2022","unstructured":"Ianevski A, Giri AK, Aittokallio T. SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples. Nucleic Acids Res. 2022;50:W739\u201343.","journal-title":"Nucleic Acids Res"},{"key":"8514_CR71","doi-asserted-by":"publisher","first-page":"v","DOI":"10.1038\/nmeth.f.353","volume":"8","author":"U Nguyen","year":"2011","unstructured":"Nguyen U, Squaglia N, Boge A, Fung PA. The Simple WesternTM: a gel-free, blot-free, hands-free Western blotting reinvention. Nat Methods. 2011;8:v\u2013vi.","journal-title":"Nat Methods"},{"key":"8514_CR72","volume":"172","author":"M Martinez-Lopez","year":"2021","unstructured":"Martinez-Lopez M, P\u00f3voa V, Fior R. Generation of zebrafish larval xenografts and tumor behavior analysis. J visualized Exp. 2021;172:e62373.","journal-title":"J visualized Exp"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08514-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08514-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08514-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T10:02:11Z","timestamp":1773914531000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08514-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8514"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08514-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2025.02.26.640375","asserted-by":"object"}]},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,25]]},"assertion":[{"value":"13 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"263"}}